These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34457284)

  • 21. Spatial Habitat Features Derived from Multiparametric Magnetic Resonance Imaging Data Are Associated with Molecular Subtype and 12-Month Survival Status in Glioblastoma Multiforme.
    Lee J; Narang S; Martinez J; Rao G; Rao A
    PLoS One; 2015; 10(9):e0136557. PubMed ID: 26368923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
    Hoff BA; Lemasson B; Chenevert TL; Luker GD; Tsien CI; Amouzandeh G; Johnson TD; Ross BD
    Acad Radiol; 2021 Dec; 28(12):1711-1720. PubMed ID: 32928633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.
    Boxerman JL; Snyder BS; Barboriak DP; Schmainda KM
    Front Oncol; 2023; 13():1061502. PubMed ID: 36776298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.
    Huang RY; Neagu MR; Reardon DA; Wen PY
    Front Neurol; 2015; 6():33. PubMed ID: 25755649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
    Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
    Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
    Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
    Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    J Neurooncol; 2011 Jun; 103(2):353-60. PubMed ID: 20848300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiomic analysis of multi-contrast brain MRI for the prediction of survival in patients with glioblastoma multiforme.
    Chaddad A; Desrosiers C; Toews M
    Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():4035-4038. PubMed ID: 28325002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
    Dhermain F
    Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
    Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
    J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudoprogression and pseudoresponse in the treatment of gliomas.
    Brandsma D; van den Bent MJ
    Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
    Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
    Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.